Multiple endocrine neoplasia type 1 medical therapy: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
No edit summary |
||
| Line 10: | Line 10: | ||
* Somatostatin analogues such as octreotide, lanreotide are used for the treatment of growth hormone secreting tumors. | * Somatostatin analogues such as octreotide, lanreotide are used for the treatment of growth hormone secreting tumors. | ||
* H2- receptor blockade and proton pump inhibitors are used to reduce the gastric output in gastrinomas. | * H2- receptor blockade and proton pump inhibitors are used to reduce the gastric output in gastrinomas. | ||
==References== | ==References== | ||
{{Reflist|2}} | {{Reflist|2}} | ||
Revision as of 14:37, 9 September 2015
|
Multiple endocrine neoplasia type 1 Microchapters |
|
Differentiating Multiple endocrine neoplasia type 1 from other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
Multiple endocrine neoplasia type 1 medical therapy On the Web |
|
American Roentgen Ray Society Images of Multiple endocrine neoplasia type 1 medical therapy |
|
Multiple endocrine neoplasia type 1 medical therapy in the news |
|
Blogs on Multiple endocrine neoplasia type 1 medical therapy |
|
Directions to Hospitals Treating Multiple endocrine neoplasia type 1 |
|
Risk calculators and risk factors for Multiple endocrine neoplasia type 1 medical therapy |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [2]; Associate Editor(s)-in-Chief: Ammu Susheela, M.D. [3]
Overview
Management
- Because the type of pancreatic endocrine cancer associated with MEN1 can be difficult to recognize, difficult to treat, and slow to progress, there are different views about the value of surgery in managing these tumors.
- One approach is to "watch and wait," using medical, or nonsurgical, treatments. According to this school of thought, pancreatic surgery has serious complications, so it should not be attempted unless it will cure a tumor or cure a hormone excess state.
- Excessive release of certain hormones-mainly gastrin-from pancreatic endocrine cancer in MEN1 needs to be treated, and medications are often effective in blocking the effects of these hormones.[1]
- Cabergoline is the treatment of choice for prolactinomas.
- Somatostatin analogues such as octreotide, lanreotide are used for the treatment of growth hormone secreting tumors.
- H2- receptor blockade and proton pump inhibitors are used to reduce the gastric output in gastrinomas.